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2/22/2108 
Dr Nadja Ehmke, M.D.  
Communicating Editor 
American Journal of Medical Genetics 
Re: 17-1067 (revised) 
 
Dear Dr. Ehmke 
Thank you for the reviews and consideration of our submission of the manuscript  ‘THE PHENOTYPIC 
SPECTRUM OF XIA-GIBBS SYNDROME’ by Jiang et al., for publication in the American Journal of 
Medical Genetics. We have revised the manuscript following the guidance of the reviewers and hope 
that it is now view favorably by the Journal.  
One suggestion by Reviewer two was to provide a single large table with all clinical data for all 20 
patients and a summary column. In doing this, we have endeavored to minimize the size of the table, yet 
it remains quite large. If it is too large for the main text we will be pleased to further modify by returning 
some data to the supplement. 
Please note we added one author since the initial submission – David R. Murdock. 
Thanks again for all your efforts. 
Sincerely 
Richard Gibbs 
 
 
Response to Reviewer’s Comments: 
 
THE PHENOTYPIC SPECTRUM OF XIA-GIBBS SYNDROME, Jiang et al. 
 
 
Comments to the Author 
 
This is a very interesting report on 20 patients with Xia-Gibbs syndrome, a condition originally 
identified by NGS analysis of a large heterogeneous cohort, in which subjects with truncating 
mutations in the same gene were identified and subsequently grouped together for analysis. With 
the advent of large scale NGS analysis of clinical populations this represents what is likely to 
become the norm in future. The original clinical descriptions were based on only 4 affecteds so 
clear information about the clinical nature of the disorder were lacking. The present publication 
provides clinical data on 20 patients and so makes a valuable contribution to the literature on this 
disorder. I think this data is a valuable addition to the sparse literature on this disorder, but I 
think some attention needs to be paid to the presentation. 
 
Thank you for the positive view of the significance of the study. 
 
There is very little novel molecular data in this manuscript, other than the reports of new 
mutations. There is no functional data to support any interpretation of the pathology or 
pathophysiology of the condition. 
 
I feel the majority of the interest here lies in the clinical descriptions. 
 
 We agree that the clinical data provide the majority of the interest and recognize the 
reviewers point. We chose the title ‘The Phenotypic Spectrum of Xia-Gibbs Syndrome’ to reflect 
this and in revision, we have endeavored to more fully emphasize the clinical observations 
throughout.  
 
 We also respectfully point out that the data also show (i) the preponderance of de novo 
truncating mutations, (ii) additional sites of mutation and (iii) the additional ‘length’ of the 
region spanned by these mutations. While secondary, we believe the mutation data do add 
novelty. Hence, while we reduced the discussion of mutation data and removed the 
Supplementary Figure S1 (see below), we have still retained some of the data and discussion. 
 
The original publications concerned 4 patients (Xia et al 2014) and 5 patients (Yang et al 2015). 
These publications highlighted different aspects of the phenotype, Xia stressing the presence of 
anatomic upper airways abnormalities, and subsequent sleep apnea. Yang et al (2015) stressed 
the presence of ataxia in their group of five patients. 
The present manuscript reports on 20 patients., but does not directly address the issues of ataxia 
or anatomic airways abnormalities highlighted in the original reports. I feel that this should be  
addressed. 
 
We have added more about ataxia and upper airway issues in the text. Ataxia is also 
added to the new Table One, describing all patient data. 
 
Other comments: 
 
(1) it is not completely clear exactly how the clinical data was obtained. It appears to me that no 
patients underwent clinical review in person, it seems the clinical data was obtained from case 
note review. This needs to be made explicitly clear. 
 
 
We apologize for the confusion. The reported data here are composite clinical data from: 
(i)  Assessment in our clinic (2 individuals),  
(ii) Observation by clinicians (MFW, JRL, JEP) at the face to face family meeting (11 
individuals), 
(iii)  review of medical records, including genetic reports (18 individuals), and 
(iv) the clinical survey with follow up (20 individuals) 
 
To clarify we have modified the text and in addition we added Supplementary Table S2 (see 
below) indicating specifically how each patient was assessed.  
 
Patient Assessment 
in Clinic 
Face to 
face 
meeting 
Medical 
Record 
Review 
Clinical 
Survey 
1 
 
X X X 
2 
 
X X X 
3 X X X X 
4 
  
X X 
5 
 
X X X 
6 
  
X X 
7 
 
X X X 
8 
  
X X 
9 
 
X 
 
X 
10 
 
X X X 
11 
  
X X 
12 
 
X 
 
X 
13 
  
X X 
14 
  
X X 
15 
  
X X 
16 X X X X 
17 
  
X X 
18 
 
X X X 
19 
 
X X X 
20 
  
X X 
 
 
 
(2) The description of the clinical phenotypes is spread across table 1, and supplementary tables 
1 and 2. I feel that all of this data could be amalgamated into a single table of clinical features, 
with summary numbers in a final column. This is a fairly standard way of presenting such data, 
and would complement fig 4. More attention needs to be given to clinical neurological findings, 
to extend the observations of Yang et al, and to confirm the presence/absence of spasticity (Yang 
et al) and the risk of seizures. These are important clinical features and will be of great value in 
the clinical setting. The MRI findings are based on review of 6 patients, but the increased volume 
of extra-axial space in the posterior fossa and hypoplasia of the corpus callosum are well 
demonstrated and should be included. 
 
 We have followed this reviewer’s guidance and combined the previous Tables 1 (main 
text) and supplementary tables 1 and 2 into a single new supplementary Table. The new table is 
now quite large (the reason that we previously divided the data) and we hope that the journal 
will permit its inclusion in the main text as the new Table 1. We also modified the text to include 
statements regarding seizure and ataxia:  
 
(3) There is detailed description of speech delay in terms of M-CHAT scores. The M-CHAT 
score is a tool in large measure used for case finding for children at high risk of ASD diagnoses. 
Despite the lengthy description of M-CHAT the authors then go to say that 5/20 children had 
diagnoses of autism, no mention is made of the methodology whereby this diagnosis was arrived 
at. I am not sure that the lengthy description of M-CHAT sits well with the paucity of the data on 
the ASD diagnosis. 
 
The Autism diagnoses in those 5 individuals was derived from the primary care clinicians 
and were communicated to us in clinical survey data and notes. We considered the heterogeneity 
of methods used by different referring physicians for reporting an ASD diagnosis in the context 
of an international study and therefore used M-CHAT as an independent source of standardized 
criteria. In the text, we endeavor to more clearly point out the relationship between the prior 
clinical assessment and the M-CHAT data. 
 
 
(4) Figure S2 illustrates relationships between age/sex and chat score and sex and speech. There 
is a clear difference in the acquisition of speech between males and females, but this could be 
easily included in the text, there is an obvious difference on X-squared testing. It is not clear 
what methodology is being used in the left-hand panel, I do not feel this contributes to 
understanding and should be left out, as well as comments accompanying it in the text. 
 
We agree with the reviewer and have deleted Figure S2. Text mentioning Figure S2 was 
also deleted accordingly.  
 
(5) Genotype-phenotype correlations are discussed on page 8 lines 48 et seq, it is not clear to me 
that any conclusions can be drawn with such small numbers. Supplementary Fig S3 seeks to 
illustrate this, but does not clarify mattes further. It is not clear what methodology is being used 
in this analysis, this figure could be omitted. 
 
We agree that the overall study is not statistically significant, given the small number of 
patients. However, we respectfully disagree as to the value of the discussion – with appropriate 
qualifiers - and propose to continue to include these data to stimulate thoughts and hypotheses 
on the possible genetic/phenotypic associations. We also note that patients with same genotype 
do not necessarily share the same phenotypes in our comparison.  
 
We agree that Fig S3 can be removed and we changed the section in the text mentioning Fig S3 
to ‘data not shown’.  
 
(6) Page 9 line 50 et seq speculates on the absence of missense mutations in this gene so far in 
the literature. This is supported by unpublished data from the authors lab. Given the difficulty of 
assigning pathogenicity to missense variation, the comments are reasonable, but hardly 
novel.  This section could be omitted without detracting from the manuscript overall. 
 
We note the reviewer’s points and indeed similar debates of the value of this discussion 
have occurred here. In submission, we opted to maintain this part of the discussion as we are 
aware of other investigators rushing to assign pathogenicity to missense de novo variants in this 
gene.  Of course, we will delete this entire paragraph if the reviewer insists – but meantime have 
abbreviated it. 
 
(7) A single cartoon of mutations would be useful, I am not sure fig S4 is necessary. 
 
Figure S4 (now Figure S1, after original S1, S2 and S3 were removed) illustrates the 
domain where the mutations are located at and the conservation of these mutation sites. 
Additional text edits were also added to illustrate this point. We feel this is an important new 
observation for readers to be aware of. 
  
Reviewer: 2 
 
Comments to the Author 
In the article „The phenotypic spectrum of Xia-Gibbs syndrome “the authors describe the largest 
cohort of individuals with AHDC1 mutations identified by WES. This article is of interest to the 
readers of this journal, I have some major and minor comments, which are listed below. 
 
Major comments: 
 
Abstract: 
The abstract does not reflect the article very well and is imprecise concerning some points. For 
example, it suggests that all individuals show thinning of the corpus callosum. Self-injury is 
mentioned as a feature, but not discussed properly in the manuscript. I suggest 
rewriting/rewording of the abstract. 
0 
Thank you for pointing this out – we have modified the abstract to indicate that only six  
of the individuals had MRIs that were available for re-review, to be shown to have thinning of 
the corpus callosum. We deleted the reference to self-injury in the abstract. 
 
All individuals were diagnosed by WES. I strongly suggest including a supplemental table listing 
all other possibly pathogenic variants identified in all individuals. 
 
We have primary whole exome data from 5 of the 20 patients. Data and genetic 
information for the rest of the patients were from genetic reports or physician letters from 
outside institutions (all were de novo except for one who was assumed de novo, wildtype only 
confirmed in mother). Supplementary table S1 was added listing other possible gene candidates 
for some of the patients.   
 
Minor comments: 
 
Some sentences are difficult to understand. For example in the Introduction: The long sentence 
starting on page 3, line 21: … the term “the suggestion of aggressive behavior” does not make 
sense.  
(line 25 instead) changed to ” indication of aggressive behavior”  
I changed to “presence” 
 
Results: First sentence of this section (it contains “molecular” twice). Please read the manuscript 
carefully to correct mistakes. 
We have removed the second ‘molecular’ 
 
Results: 
Page 6, line 3: What does M-CHAT stand for? Please include this information. 
M-CHAT has been spelled out as ‘Modified checklist for Autism in Toddlers’ 
 
Page 6, line 24: Six out of 20 patients are 30%, not 31.6%. Please change. 
Corrected 
 
Discussion: 
Page 10, second and third paragraph: Please reword the last sentences of these paragraphs: .. 
suggest … significantly… Data on significance for male patients and the likelihood of being 
non-verbal is included, but there is not data on the significance of the risk of developing 
scoliosis. 
Data indicating the significance of the risk of developing scoliosis is in page 7, line 26, 
p=0.018, compared to up to 5.2% prevalence in general population.  
 
Page 10, line 50: please reword the last sentence of this paragraph: … “for symptoms that may 
be greater in individual cases” … what does that mean? 
‘greater’ has been changed to ‘more severe’ 
 
Figure legends: 
Figure 1: The figure legend includes the description of an asterix, but I cannot find it in the 
figure (?). Please change the figure accordingly. 
These have been  been added to Figure 1 
 
Figure 2: Please include that M-CHAT scores indicate risk for autism. It is not mentioned in the 
figure legend. 
M-CHAT scores with high risks are being indicated in the legend.  
 
Figure 4: Please include a short description of some overlapping facial features. 
A short description of some overlapping facial features are included: ‘overlapping facial 
features include broad forehead, hypertelorism, flat nasal bridge and thin upper lip’.  
 
Supplementary table 1: Which height measurement is used? Please include explanation. No 
height available for patient 12 and 20? 
Height was shown in percentage (WHO child growth standards 2-5yo 
http://www.who.int/childgrowth/standards/height_for_age/en/ and WHO growth references for 
5-19yo http://www.who.int/growthref/en/, percentage for two adult patients are assessed as 19 
year olds).  The above information has been added to the table legend. Heights for patients 12 
and 20 were not available at the time of manuscript submission. Height information for 20 was 
currently available and has been added (0.01).   
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ABSTRACT:  1 
Xia-Gibbs syndrome (XGS: OMIM # 615829) results from de novo truncating mutations within 2 
the AT-Hook DNA Binding Motif Containing 1 gene (AHDC1). To further define the phenotypic 3 
and molecular spectrum of this disorder, we established a Xia-Gibbs Syndrome Registry and 4 
recruited patients from the worldwide pool of approximately 60 probands. Additional de novo 5 
truncating mutations were observed among 25 individuals, extending both the known number 6 
of mutation sites and the range of positions within the coding region that were sensitive to 7 
alteration. Detailed phenotypic examination of 20 of these patients via clinical records review 8 
and data collection from additional surveys showed a wider age range than previously 9 
described. Data from developmental milestones showed evidence for delayed speech and that 10 
males were more severely affected. Neuroimaging from six available patients showed an 11 
associated thinning of the corpus callosum and posterior fossa cysts. An increased risk of both 12 
scoliosis and seizures relative to the population burden was also observed.  Data from a 13 
modified autism screening tool revealed that XGS shares significant overlap with autism 14 
spectrum disorders. These details of the phenotypic heterogeneity of XGS implicate specific 15 
genotype/phenotype correlations and suggest potential clinical management guidelines. 16 
 17 
 18 
 19 
  20 
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INTRODUCTION: 1 
Xia-Gibbs syndrome (XGS: OMIM #615829) is a newly described disorder characterized 2 
by developmental delay, hypotonia, speech delay, sleep apnea and seizures(Xia et al., 2014). 3 
Patients with XGS have de novo truncating mutations within a critical region of the AT-Hook 4 
DNA Binding Motif Containing 1 gene (AHDC1).  Probands present with features that are 5 
associated with several different syndromes and are observed in many undiagnosed patients 6 
who likely harbor other genetic disorders, making DNA testing and the establishment of 7 
molecular diagnosis the primary diagnostic tool for XGS.  Indeed, the original identification of 8 
the disorder depended on the identification of molecular variation in AHDC1, rather than 9 
recognition of a distinctive set of shared clinical features.  This initial report of XGS focused on 10 
four probands and their relatives who were clinically assessed after identification of AHDC1 11 
truncating alleles, revealing a shared set of phenotypic features(Xia et al., 2014). Subsequently, 12 
an additional seven patients were described with features consistent with the original four that 13 
were reported(Yang et al., 2015). These published cases each have truncating AHDC1 14 
mutations, but display clinical heterogeneity, including the variable occurrence of seizures, the 15 
extent of anomalies detectable by brain MRI, differences in the overall levels of cognitive 16 
function, the age of language development and the possible presence of aggressive or unruly 17 
behavior in some cases(Xia et al., 2014; Yang et al., 2015). Whether this reflects allelic 18 
heterogeneity and if specific genotype/phenotype correlations can be discerned, remains 19 
unknown. 20 
Approximately 60 probands worldwide have now been identified through additional 21 
publication(Bosch et al., 2016; Garcia-Acero & Acosta, 2017; Miller et al., 2017; Park, Kim, Jang, 22 
& Jang, 2017; Quintero-Rivera et al., 2015), self-referral, physician contact, and social media. 23 
Xia-Gibbs syndrome is, therefore, an example of a disorder where the diagnostic impact of 24 
whole-exome sequencing, when combined with social media, has allowed families to rapidly 25 
build networks, establish support groups and participate as stakeholders in research(Enns et al., 26 
2014).  27 
To more systematically evaluate the consequences of de novo truncating mutations in 28 
this gene, and to provide a resource for the future study of XGS and AHDC1-related disorders, 29 
Jiang et al. 4 
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we established a Xia-Gibbs Syndrome Registry to gather genotype and phenotype data from 1 
multiple families. The detailed evaluation of the molecular and clinical spectrum of 20 cases 2 
provides a basis for both improved forecast of prognoses and support for research studies.  3 
METHODS: 4 
Identification of AHDC1 Families: Sixty families were identified worldwide via self-reporting, 5 
physician referral, and social media.  6 
Registry: A Registry was established utilizing RedCap (Research Electronic Data Capture), which 7 
is a secure, web-based application designed to support data capture for research studies(Harris 8 
et al., 2009). This application was initially housed in a HIPAA compliant environment hosted by 9 
Amazon Web Services (AWS) and later migrated to a local, compliant host environment to allow 10 
all the records in the registry to be maintained in a confidential environment.  11 
Ethics, Consent, and Permissions: The infrastructure for the Registry and outreach to identified 12 
probands and families was approved by the Baylor College of Medicine Institutional Review 13 
Board. Invitation emails were sent to parents and caretakers, and positive responders were 14 
provided informed consent for Registry participation. The Registry includes full contact 15 
information, detailed patient records from each participant’s clinical consultations and parent 16 
responses to a questionnaire designed to capture clinical and developmental features of the 17 
affected child. A second IRB approved Protocol was used to further consent individuals who 18 
were in the Registry, for whom there were additional requests for research participation. 19 
Clinical Ascertainment: Parents of probands consented to their participation in the registry, 20 
together with their affected children. Participants join the registry by completing an initial 21 
survey and by providing their contact information and a genetic testing report documenting a 22 
pathogenic variant in the AHDC1 gene. A further clinical survey was then administered 23 
(complete survey details are in the supplementary materials).  In addition to the clinical survey, 24 
14 probands and their families attended a clinical and family conference held in April of 2017, in 25 
Houston, Texas. At that conference, clinical observations from the survey data were clarified by 26 
the family and physicians. Additional medical records and MRI images were also obtained for 27 
some of the subjects. Available MRI images were independently reviewed by a pediatric 28 
neuroradiologist (JVH).  29 
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Facial Feature Analysis: Facial feature analyses were performed using the Facial Dysmorphology 1 
Novel Analysis software (FDNA, Inc. Boston, MA) and facial images provided by families. A mask 2 
depicting the composite, characteristic appearance of XGS was created.  3 
Data Analysis: Statistical analyses were performed using R. The Fisher exact test was used to 4 
compare the language ability between male and female patients. A binomial test was used to 5 
compare the prevalence of scoliosis in the patients with the frequency in the general 6 
population. 7 
RESULTS:  8 
Overview of the patients, gene, and AHDC1 mutations: 9 
Twenty individuals with de novo truncating AHDC1 mutations had detailed clinical 10 
assessments and were included for the phenotypic comparison described in this study. These 11 
individuals represent a subset of the 60 families described worldwide as of November 2017, for 12 
whom our review of the available records of mutation data was consistent with a molecular 13 
XGS diagnosis in 34 families. Of these 34 families, 25 joined the registry and all but five families 14 
provided sufficient clincial data for inclusion.  15 
The 20 described individuals include six previously published and 14 novel cases. 16 
Medical records were sought and successfully obtained for 18 of the probands, while two 17 
others were determined to have already provided sufficient clinical information.  MRI images 18 
and reports were collected and independently reviewed by a pediatric neuroradiologist, for six 19 
cases. 20 
We directly confirmed the mutational data by DNA sequencing in 13 individuals, where 21 
samples were available to be tested. The confidence in the accuracy of the mutation data from 22 
the remaining seven cases was based upon the availability of clinical diagnostic reports from 23 
major providers.  Figure one shows the position of all 25 mutations from XGS patients in the 24 
Registry. In five of the cases described here, we also had data from whole exome sequencing 25 
and we considered other gene candidates as contributing to disease, apart from AHDC1. We 26 
were able to exclude all such candidates based on phenotype mismatch, frequency, or lack of a 27 
second variant contributing to an established recessive mode of inheritance (Table S1). A de 28 
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novo NF1 variant reported in one individual was excluded as contributing to the clinical profile, 1 
due to the phenotype mismatch. 2 
In addition to the more severely affected individuals with truncating mutations who are 3 
included in the Registry, one less severe case has been putatively associated with a de novo 4 
heterozygous missense mutation in AHDC1. This patient is diagnosed with autism spectrum 5 
disorder, without other reported features of XGS. Confirmation of missense mutations leading 6 
to mild phenotypes would be of considerable interest for delineating gene function and disease 7 
pathology. At this time, however, it is impossible to eliminate mutations in other loci as the 8 
cause of this patient's disorder. A search for mutations contributing to this individual's 9 
phenotype is underway, and so these data are not included in the present report. 10 
Mutation position: 11 
The previously reported cases represented nine distinct mutations that spanned the 12 
amino acid positions in the AHDC1 gene product from codon 375 to 1270 (Figure 1).  In the 13 
present report, we now describe an additional 14 cases, including 11 novel AHDC1 truncating 14 
mutations, extending this range from codon 262 to 1330 and doubling the number of known 15 
pathogenic mutation sites of AHDC1. There are three recurring mutations in our cohort, 16 
including the previously reported p.Cys791Trpfs*57 (c. 2373_2374delTG), which is now known 17 
to be present in 4/20 (20%) of these unrelated patients. Two additional newly observed 18 
mutations, p.Arg925* (c.2773C>T) and p.Gln970* (c.2908C>T), each occurred in two patients.  19 
The mutations in the 20 probands all are predicted to lead to premature chain 20 
termination (PCT) during translation and include stop-gain changes (9 sites) or frameshifts 21 
leading to downstream truncation events (11 Sites). The truncation peptide sequences 22 
predicted by conceptual translation to arise as a result of the frameshift mutations did not 23 
show high homology to other proteins. Two different mutations gave rise to similar truncation 24 
peptides and, with one exception, all truncation products terminate within the boundaries of 25 
other non-sense mutation sites. 26 
Patient phenotype:  27 
The current ascertainment of the clinical spectrum associated with XGS is described in 28 
Table 1. Ascertainment for the reported cases includes data from initial clinical visits, family 29 
Jiang et al. 7 
 
7 
 
survey, and subsequent consultancy (see supplementary Table S2 for details). The 20 cases 1 
include 11 males and nine females, with a median age of 8 years old. Two of the participants 2 
were more than 18 years old.   3 
Language and Cognitive ability:  4 
Overall Cognitive Ability: A diagnosis of autism, or autism spectrum disorder, had previously 5 
been reported in 5 of the 20 patients described here (25%). Methods for assessing autism 6 
spectrum disorder can be heterogeneous, hence we used the Modified Checklist for Autism in 7 
Toddlers (M-CHAT) as a standardized method to assess cognitive ability in the individuals in the 8 
cohort (Robins et al., 2014). This tool is widely used as a preliminary screen for children to 9 
identify increased autism risk, for which a formal, full neuropsychological evaluation would be 10 
recommended. In general practice, those who have a score indicating medium or high risk of 11 
autism will receive further testing. The 20 patients had a median M-CHAT score of 8 (0 ~ 14). Of 12 
these, 5 (25%) had an M-CHAT score less than 2, which is considered low risk for autism, 4 13 
(20%) had an M-CHAT score between 3~7, at medium risk for autism, and 11 (55%) had an M-14 
CHAT score between 8~20 and were at high risk for autism.  All five individuals who had been 15 
diagnosed with autism, or autism spectrum disorder prior to this study, had an M-CHAT score 16 
higher than 8 (Figure 2A).  17 
In addition to M-CHAT, the patients were assessed on their language skills and on the capability 18 
to follow simple commands (Figures 2B, 2C). A total of 18 (90%) of 20 patients were reported as 19 
able to follow simple commands, with a median age of 3.9 (1.5~8) years (Figure 2C).  20 
Timing of Speech: Eight out of 20 patients (40%) were reported to have no speech, four (20%) 21 
were reported to use less than 50 words, two (10%) were reported to have a vocabulary of 22 
more than 50 words but do not speak in full sentences, and six (30%) patients were reported to 23 
use complete sentences with a vocabulary of more than 200 words (Figure 2B and 24 
Supplementary Figure S2B). Among the 12 patients who use at least one word other than 25 
‘mama’ or ‘dada’, the median age for using one word is 2.75 (1~5) years, while the median age 26 
for using two words together is 3.5 (2~6) years (Figure 2C). These data are consistent with a 27 
relationship between gender and speech as male patients are significantly more likely to be 28 
non-verbal than female patients (p < 0.01). One of the male patients is two years old, which is 29 
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younger than the median age at which first words were spoken, however, the p-value is still 1 
<0.01 when he is removed from this analysis. It is noteworthy that all the patients reported 2 
with no speech are male (Figure 2B).  3 
Correlation of M-CHAT and Speech: Multilinear linear regression showed that a linear 4 
relationship exists between the M-CHAT score, the square root of age and language capability 5 
ratings (0=nonverbal; 1=using less than 50 words; 2=not using sentence but using more than 50 6 
words; 3=using sentences with a vocabulary of more than 200 words). The equation is: 7 
M-CHAT score = 1.99* sqrt(age) – 2.27 * language capability rating (adjusted R2 = 0.42). 8 
This indicates that the M-CHAT score increases with age, but the rate of increase slows down 9 
with the gain of age. It also suggested for patients of the same age, for every point increase in 10 
language capability rating, the M-CHAT score decreases by approximately 2 points.   11 
Neurology:  12 
Abnormal MRI: An abnormal MRI was reported in 12 out of 20 (60%) patients who have had 13 
MRI performed. MRI images for re-review were available for six patients. We found that 6/6 14 
had thinning of the corpus callosum (Figure 3, compare B-F to “control” individuals A and D). In 15 
addition, several subjects were found to have a cyst in the posterior fossa (Subject 4, Figure 3B, 16 
Subject 3 Figure 3E, Subject 7, Figure 3H).   17 
Seizures: Seizures were reported in six out of 20 (30%) patients. The median onset age of 18 
seizure is four years old (9 months ~ 12 years old). An abnormal EEG was reported in three out 19 
of these six (50%) patients.  20 
Timing of Walking: Independent walking is reported in 16 out of 20 patients (80%), with median 21 
beginning walking age of 2.5 (1.5~6) years. All the patients who are not able to walk 22 
independently are male. However, there is no significant difference between the ability to walk 23 
independently between male and female patients (p = 0.09).  Hypotonia is reported in 19 out of 24 
20 patients (95%). 25 
Other significant features:  26 
Scoliosis: Scoliosis was reported in four of 20 (20%) patients (ages 10~21 years), and three had 27 
received surgery for the condition. Compared to a general population prevalence of idiopathic 28 
scoliosis of 0.47 to 5.2% with an age of onset of 10 to 15 years, the risk of scoliosis in XGS 29 
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individuals is significantly increased (p = 0.018, compared to 5.2% prevalence)(Konieczny, 1 
Senyurt, & Krauspe, 2013; Mirtz, Thompson, Greene, Wyatt, & Akagi, 2005). No sex bias was 2 
apparent. 3 
Airway/Sleep: Sleep apnea was reported in eight out of 20 patients (40%), three of these eight 4 
patients (37.5%) use respiratory support during sleep.  5 
Vision: Strabismus was reported in eight out of 20 patients (40%).  6 
Dysmorphic features: Facial features (Figure 4A) consistently revealed dysmorphic features such 7 
as broad forehead, hypertelorism, flat nasal bridge, and thin upper lip (Table 1). These features 8 
are also shown in the composite mask depicting the characteristic appearance of XGS patients 9 
(Figure 4B).  To date, no patient has been clinically diagnosed based on a recognizable pattern 10 
of facial dysmorphisms, or a facial gestalt.  11 
Aggressive Behaviors: Aggressive behavior in at least one patient was suggested by Yang et 12 
al.(Yang et al., 2015). We were unable to ascertain any history of overtly aggressive behavior in 13 
the reported cases, although several parents described a history of self-injury. 14 
Genotype and phenotype association: 15 
To explore the correlation between the specific site of mutation and phenotype, we 16 
compared three sets of patients who share the same mutations. Patients 1, 10, 18 and 19 share 17 
mutation p.Cys791Trpfs*57, patients 6 and 17 share mutation p.Arg925* and patients 9 and 12 18 
share mutation p.Gln970*. For the mutation p.Cys791Trpfs*57, all four patients are verbal and 19 
reported to have sleep apnea and abnormal brain MRI.  Seizures were reported in three of the 20 
four patients. Strabismus and a high-risk MCHAT score were reported in two of the four 21 
patients. It is challenging to compare the two patients with mutation p.Arg925* as one of them 22 
(patient #6) is only three years old, and is yet to reach some developmental milestones. 23 
Patients 9 and 12 were each reported to be verbal, using sentences with a vocabulary of more 24 
than 200 words. They were both reported to have normal MRI and EEG. They achieved 25 
developmental milestones, such as using words and walking, at similar ages. Strabismus was 26 
reported in patient 9 but not in patient 12.   27 
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To further explore correlations between the mutations and phenotypes, multiple 1 
phenotypes were plotted against the mutation sites (data not shown). No significant 2 
association was observed.  3 
DISCUSSION: 4 
The ability to aggregate data from the observation and care of individuals with XGS is a 5 
key step for clinical management, family counseling and molecular research into the condition. 6 
A concerted effort to identify patients worldwide has identified approximately sixty families, of 7 
whom 20 are described in detail here, including 14 not previously reported. The ascertainment 8 
combined records from initial clinical visits and subsequent clinical and family-reported 9 
findings. 10 
Previously known truncating mutations in AHDC1 leading to XGS were observed to 11 
cluster around the middle of the coding region (from p.Gly375Argfs∗3 to p.Gln1270Argfs∗75)2, 12 
and this report expands these positional boundaries (from p.Gln262* to p.Ser1330*, Figure 1). 13 
Importantly, the number of different known mutations increased, revealing the sensitivity of 14 
the protein to truncating events throughout much of its length. All mutations discussed here 15 
are de novo in the proband. The mutations each are truncating and lead to a shorter predicted 16 
protein. 17 
The AHDC1 gene contains a single coding exon. Although the newly reported mutations 18 
do not shed further light on the putative functional regions of the AHDC1 protein, our database 19 
searches reveal, for the first time, domains shared with REV3L (DNA polymerase zeta catalytic 20 
subunit) and/or KIAA2022, a target for truncating mutations that cause intellectual 21 
disability(Gan, Wittschieben, Wittschieben, & Wood, 2008; Van Maldergem et al., 2013) (Figure 22 
1; Supplementary Figure S2). The cross-species alignments reveal striking conservation across 23 
multiple domains with both REV3L and KIAA2022. REV3L is the catalytic subunit of polymerase 24 
zeta and is implicated in genome stability and DNA translesion repair13. It is therefore 25 
conceivable that AHDC1 may play a role in complexes that involve DNA repair through its ability 26 
to interact with the DNA via the AT-hook domains. Previous work has shown the interaction of 27 
AHDC1 with Tax Interaction Protein 1 which was proposed to occur in vivo under DNA 28 
damaging conditions(Shalaby, Hampson, Oliver, & Hampson, 2012). 29 
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The preponderance of de novo truncating pathogenic AHDC1 alleles could indicate that 1 
missense mutations do not cause disease.  Alternatively, the absence of pathogenic missense 2 
variants may simply reflect the early period of discovery and reduced ascertainment due to a 3 
potentially milder phenotype. A similar, illustrative example is Bainbridge-Ropers Syndrome 4 
(BRS: OMIM #615485), where severe phenotypes resulting from de novo truncating mutations 5 
in four cases led to the initial disease gene identification of ASXL3(Bainbridge et al., 2013) and 6 
follow up discovery of additional truncating mutations(Balasubramanian et al., 2017). Recently, 7 
however, compound missense heterozygous alleles in ASXL3 have been associated with mild 8 
forms of BRS(Giri et al., 2017) and by analogy, future observation of missense mutations in 9 
AHDC1 leading to pathogenicity cannot be discounted. 10 
The absence of well-characterized cases in this cohort with large deletions that either 11 
interrupt or overlap the gene may reflect a dominant negative mechanism of pathogenesis or 12 
the difficulties of precise ascertainment of the disorder. We note twelve patients with copy 13 
number loss or gain covering regions of the genome ranging from 39kb to 19Mb at or near 14 
AHDC1, recorded in the DECIPHER database(Firth et al., 2009; 15 
https://decipher.sanger.ac.uk/search?q=AHDC1#consented-patients/results). Seven of these 16 
share similar phenotypes with XGS patients such as developmental delay, hypotonia, and 17 
dysmorphic features, one has ‘ankyloglossia’ and four have no phenotype information 18 
available. The interpretation of the phenotypes of these patients is confounded by the 19 
presence of genes near AHDC1 for which mutation can independently result in developmental 20 
disorders(Rocha, Vasques, Santos, & Paiva, 2016). These cases, therefore, warrant further 21 
investigation, including the precise mapping of the boundaries of the lesions. 22 
Some AHDC1 mutation positions correlate with clinical observations and warrant follow 23 
up studies with much larger sample sizes to establish robust genotype-phenotype correlations. 24 
Patients with mutations occurring near the C-terminus of the protein (p.Ser1258*, 25 
p.Gln1270Argfs*75 and p.Ser1330*) are non-verbal with high M-CHAT scores, while the patient 26 
with the early stop-gain mutation p.Gln262* uses sentences and has an M-CHAT score of 1, 27 
which may suggest milder features. This may indicate that nonsense and frameshift variants 28 
closer to the C-terminus have a more severe clinical impact.  Comparison of individuals with 29 
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identical mutations suggests that there is heterogeneity among patients, even with the same 1 
alteration in AHDC1 gene. To further establish the correlation between phenotype and specific 2 
mutation site, larger numbers of patients will be needed to be analyzed.  3 
The participating families indicated a wider range of patients’ age than previously 4 
recognized. The median age was eight years – but two of the patients were adults (nineteen or 5 
older). As this is a newly described syndrome and younger children are more likely to seek 6 
genetic diagnosis, the true age distribution in the population is not known. This is a particularly 7 
important question for families as they plan ongoing care. The parents of older children 8 
reported challenging behavioral issues during puberty but declined to describe the patients as 9 
aggressive.  10 
Approximately one-half of the patients either had a diagnosis of autism, autism 11 
spectrum disorder or were considered at high risk due to their M-CHAT assessment. The precise 12 
relationship between ASD and ID is controversial and complex(Matson & Shoemaker, 2009). In 13 
general, the younger children in this group exhibit hallmarks of ID, however, the relative 14 
cognitive abilities of older children reveal higher function and therefore are more likely to 15 
suggest ASD. Relatedly, ASD has an elevated frequency in males(Matson & Shoemaker, 2009), 16 
and the data here from the assessment of language capabilities suggest that male XGS patients 17 
are significantly more likely to be non-verbal than female patients. This feature warrants 18 
further investigation. 19 
Previous reports on XGS have focused on somewhat different clinical features. In 20 
particular, clarification of the neurological features was more in-depth from this larger group of 21 
subjects.  We observed that six patients (30%) developed seizure s, while 13 (65%) had ataxia, 22 
in line with previous reports, further reinforcing the CNS involvement in XGS.     23 
Upper airway abnormalities also appear to be a common feature in XGS. In the original 24 
report, 3 of 4 probands had obstructive sleep apnea, and the 4th had suspected tracheomalacia 25 
in infancy (Xia et al., 2014). Sleep apnea was present in 40% of the XGS cases described here, 26 
with many requiring continuous positive airway pressure (CPAP) at night. This suggests careful 27 
monitoring of airway function is essential and there should be a low threshold for referral to 28 
pulmonology.  29 
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A surprising finding from this detailed assessment was the frequency of scoliosis among 1 
XGS individuals. Scoliosis was not included as a characteristic phenotype in previous 2 
publications (only reported in patient#2 in Yang et al.)(Yang et al., 2015).  However, the usual 3 
age-at-onset of the feature is 10~15 years old(Konieczny et al., 2013) while the median age for 4 
the 11 patients reported here was five years (1.5 ~ 16) at the time of publication. Our study, 5 
therefore, suggests that patients are at significantly increased risk for developing scoliosis and 6 
would benefit from an orthopedic referral when appropriate.  7 
The evaluation here suggests several features of XGS for which early diagnosis and 8 
regular surveillance can be of clinical benefit.  All individuals should undergo detailed 9 
assessment by a physician who is familiar with the condition, with annual (more frequent 10 
during the first years of life) assessments of growth including height, weight, and head 11 
circumference to identify those at risk of failure to thrive or short stature necessitating 12 
intervention, and clinical evaluation for scoliosis. Neurodevelopmental delay is a ubiquitous 13 
feature of this condition, and regular childhood developmental assessments with early 14 
initiation of therapies will maximize developmental potential. Given the high frequency of 15 
structural brain anomalies, a baseline brain MRI should be considered, particularly if neurologic 16 
abnormalities such as hypotonia are present on exam.  Neurologic and ophthalmologic 17 
involvement in some individuals may warrant consultation by the appropriate specialists. An 18 
evaluation for obstructive sleep apnea as well as an upper airway assessment should also be 19 
considered. Together, these practices can both provide better clinical diagnosis and suggest 20 
management strategies for symptoms that may be more severe in individual cases. 21 
XGS has multiple features overlapping with autism, suggesting that XGS should be on 22 
the differential for unexplained intellectual disability and developmental delays. There are likely 23 
older children, adolescents, and adults previously diagnosed with an autism spectrum disorder 24 
or intellectual disability who have XGS and would benefit from a clinical genetics referral. 25 
 26 
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Figure legends: 1 
Figure 1: Schematic representation of mutations identified in 25 XGS patients that have 2 
participated in the XGS Registry. Mutations in five individuals who are not clinically assessed in 3 
detail, in this study, are indicated by an asterisk. Previously reported variants are indicated 4 
below the line, newly reported mutations above. The x-axis shows amino acid positions in the 5 
encoded protein, pink rectangles indicate AT-Hook domains, green rectangles indicate REV3L 6 
homology domains, purple rectangle indicates KIAA2022 homology domains and grey rectangle 7 
indicates REV3L and KIAA2022 homology domains. Green circles indicate frameshift variants, 8 
yellow indicates nonsense variants (see Supplementary Material for further description of 9 
homologies and conservation). 10 
Figure 2: A) M-CHAT score of the 20 patients. Patients with M-CHAT scores 8~20 are considered 11 
high risk and those who scored 0~7 are considered to have medium-low risk. B) Language 12 
capability distributed by age and sex. C) Age at onset distribution of patients who achieve 13 
different milestones (from up to bottom): independent walking, using first word, using two 14 
words together and following simple commands. For patients who have not reached any of the 15 
milestones, their current ages are shown in red in each panel.  16 
Figure 3: Brain MRI features of the subjects, unless otherwise indicated a Sagittal T1 image is 17 
shown 18 
A. A control subject (a clinical MRI for history of minor head trauma) in a subject at age 13 19 
months showing a typical corpus callosum (red arrow) 20 
B. Subject 4 at age 6 months, shows thinning of the corpus callosum posteriorly (red 21 
arrow) in addition there is a large extra-axial fluid space posterior to the cerebellum 22 
C. Subject 2 at age 6 months, although the young age limits the assessment, the corpus 23 
callosum appears thin (red arrow) 24 
D. A control subject (a clinical MRI for history of seizure) in a subject at age 3 years showing 25 
a typical corpus callosum (red arrow) 26 
E. Subject 3 at age 10 years, shows thinning of the corpus callosum (red arrow), 27 
particularly in the posterior portion, there is also a large extra-axial fluid space posterior 28 
to the cerebellum 29 
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F. Subject 2 (also shown in C) now at age 1 year, a later study confirms the suspicion of the 1 
6-month study suggesting thinning of the corpus callosum  2 
G. Subject 7 at age 5 years, a T2 axial image shows the extra-axial fluid space around the 3 
cerebellum is larger than normal and dysmorphic in appearance 4 
H. Subject 7 at age 5 years, a T1 sagittal image shows thinning of the corpus callosum and a 5 
large extra-axial fluid space posterior to the cerebellum.   6 
Figure 4: (A) Frontal face images of some of the patients (accession number in this study are 7 
shown at top left corner) (B) A computer generated masking depicting the characteristic 8 
features of Xia-Gibbs syndrome. This image was generated using the FDNA software. 9 
Overlapping features include a broad forehead, hypertelorism, flat nasal bridge and thin upper 10 
lip. 11 
List of Supplementary Materials:  12 
Supplementary Figures:  13 
Figure S1: Protein alignments illustrating conservation domains between human AHDC1 and its 14 
orthologs and homologs. 15 
Supplementary Tables:  16 
Table S1: Other possible gene candidates for some of the patients.  17 
Table S2: Clincial/phenotype assessment method for each patient. 18 
Other Supplementary Files:  19 
Clinical survey 1of2: general clinical history and developmental questions 20 
Clinical survey 2of2: M-CHAT R/F (Robins et al., 2014) 21 
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TABLES 1 
Table One: Detailed patient phenotypes. Height was shown in percentage (WHO child growth 2 
standards 2-5yo http://www.who.int/childgrowth/standards/height_for_age/en/ and WHO 3 
growth references for 5-19yo http://www.who.int/growthref/en/, percentage for two adult 4 
patients are assessed as 19-year-olds). 5 
 6 
Footnotes: 7 
*References: 1, Xia et al., 2014; 2, Yang et al. 2015. 8 
** Language: 1. No words or few words; 2. no sentence but >50 words; 3. fun sentence > 200 9 
words  10 
 11 
 12 
 13 
 14 
 15 
 16 
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  1 
PATIENT
1
2
3
4
5
6
7
8
9
10
Reference*
#1 (patient 1)
#2 (patient 5)
#2 (patient 1)
#1 (patient 3)
M
utation
Nucleotide change
c.2373_2374delTG
c.3809delA
c.2644C>T
c.2520del
c.2229delG
c.2773C>T
c.1945delG
c.2062C>T
c.2908C>T
c.2373_2374delTG
Protein change
p.Cys791Trpfs*57
p.Gln1270Argfs*75
Gln882*
Arg841Alafs*91
Ser744Profs*188
Arg925*
Ala649Profs*83
Arg688*
Gln970*
Cys791Trpfs*57
Age
5 yo
12 yo
10 yo
9 yo
13 yo
3 yo
4
20
6
12 yo
Gender
F
M
M
M
M
M
M
F
F
M
Ethnicity
W
hite
w
hite/asian
w
hite
w
hite
w
hite
w
hite
w
hite
w
hite
w
hite
w
hite
Grow
th
Height
0.05
0.01
0.05
0.15
0.03
<0.01
<0.01
>0.99
(0.05,0.15)
0.05
Scoliosis
N
N
Y
N
Y
N
N
Y
N
Language
M
-CHAT Score
12
6
9
13
10
5
9
10
1
2
Prior Autism
 diagnosis
Y
N
Y
N
N
N
Y
Y
N
N
Current language**
1
0
0
0
0
0
0
2
3
3
Age at first w
ord
4 yo
NA
NA
NA
NA
NA
NA
5 yo
2.5 yo
12 m
o
Age, tw
o w
ords together
NA
NA
NA
NA
NA
NA
NA
6 yo
3.5 yo
24 m
o
Age follow
ing com
m
and
2 yo
8 yo
8 yo
NA
4 yo
23 m
o
3 year 9 m
o
4 yo
3-4 yo
18 m
o
M
obility
Hypotonia diagnosis
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Independent w
alking
Y
Y
Y
N
Y
N
Y
Y
Y
Y
Age independent w
alking
3 yo
6 yo
3 yo
NA
3 yo
NA
3 year 5 m
o
22 m
o
2.5 yo
18 m
o
Sleep/airw
ay
Sleep apnea
Y
N
N
N
Y
Y
Y
N
N
Y
Breathing support
Y
N
N
N
N
N
N
N
N
Y
Neuro
M
RI
abnorm
al
abnorm
al
abnorm
al
abnorm
al
norm
al
norm
al
abnorm
al
abnorm
al
norm
al
abnorm
al
EEG
norm
al
NA
norm
al
norm
al
NA
norm
al
NA
norm
al
norm
al
abnorm
al
Seizure 
N
N
Y
N
N
N
N
Y
N
Y
Age at first seizure 
9 yo
9 m
o
3 yo
Ataxia
Y
Y
N
Y
N
N
Y
Y
Y
Y
Vision
Glasses/contacts
Y
No
N
Y
N
N
Y
Y
N
N
Vision acuity
n.asc.
n.asc.
n.asc.
m
ild m
yopia
n.asc.
n.asc.
slight astig.
n.asc.
n.asc.
prism
atic lenses
Strabism
us
Y
N
Y
N
N
Y
N
N
Y
N
Dysm
orphic features
Sm
all ear lobes
N
NA
Y
N
N
N
N
N
N
Y
Upturned earlobes
N
NA
N
Y
N
N
Y
N
N
N
Low
-set ears
N
NA
N
Y
N
N
N
Y
N
N
Protuberant ears
N
NA
Y
N
N
N
N
N
Y
Y
Deep-set eyes
N
NA
N
N
Y
Y
N
Y
N
N
Upslanting palpebral fissures
N
NA
N
Y
N
N
N
N
Y
N
Dow
nslanting palpebral fissures
N
NA
N
N
Y
N
Y
N
N
N
M
ild ptosis
N
NA
N
Y
N
Y
N
N
N
N
Esotropia
N
NA
N
Y
N
Y
N
N
Y
N
Hypertelorism
N
NA
Y
N
N
N
Y
Y
Y
N
Flat nasal bridge
Y
NA
Y
Y
N
Y
Y
N
Y
N
M
icrognathia
N
NA
N
N
N
Y
N
N
N
N
Thin upper lip
Y
NA
Y
Y
Y
Y
Y
Y
Y
Y
Broad forehead
Y
NA
N
Y
N
Y
Y
Y
Y
N
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  1 
Patient
11
12
13
14
15
16
17
18
19
20
SUM
M
ARY
Reference*
#1 (patient 2)
#2 (patient 6)
M
utation
Nucleotide change
c.2691delA
c.2908C>T
c.784C>T
c.3989C>A
c.2415delG
c.2898delC
c.2773C>T
c.2373_2374delTG
c.2373_2374delTG
c.3773C>G
Protein change
V898W
fs*34
Gln970*
Gln262*
Ser1330*
Leu806Trpfs*126
Tyr967Thrfs*175
Arg925*
Cys791Trpfs*57
Cys791Trpfs*57
Ser1258*
Age
4 yo
11 yo
6 yo
17 yo
6 yo
8 yo
6 yo
8 yo
21yo
2yo
8yo (2~21yo)
Gender
F
F
F
M
F
F
F
M
M
M
Fem
ale 9 (45%
)
Ethnicity
w
hite
w
hite
w
hite
w
hite
w
hite
Asian
w
hite
w
hite
w
hite
w
hite
W
hite 18 (90%
) 
Grow
th
Height
<0.01
NA
0.05
<0.01
(0.25,0.5)
<0.01
(0.15,0.25)
0.15
<0.01
0.01
Scoliosis
N
N
N
N
N
N
N
N
Y
N
4 (20%
) 
Language
M
-CHAT Score
0
9
1
14
0
4
8
4
10
13
8.5 (0~14) 
Prior Autism
 diagnosis
N
N
N
Y
N
N
N
N
N
N
5 (25%
)
Current language**
1
3
3
0
3
1
1
3
2
0
1 (0~3) 
Age at first w
ord
2.5 yo
2 yo
4 yo 
NA
around 3 yo
UKN
around 2.5-3 yo
2 yo 
5 yo
NA
2.75yo (1~5yo)
Age, tw
o w
ords together
3.5 yo
3 yo
5 yo
NA
3 yo
4 yo
NA
2 yo 
7 yo
NA
3.5yo(2~7yo)
Age follow
ing com
m
and
2 yo
6 yo
5 yo
5 yo
2 yo
6 yo
3 yo
4 yo
3 yo
NA
3.875(1.5~8yo) 
M
obility
Hypotonia diagnosis
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
19 (95%
)
Independent w
alking
Y
Y
Y
Y
Y
Y
Y
Y
N
N
16 (80%
) 
Age independent w
alking
2.5 yo
2 yo
3 yo
19 m
o
2 yo
2yo
2 year 4 m
o
4 year
NA
NA
2.5yo (1.5~6yo) 
Sleep/airw
ay
Sleep apnea
N
N
N
N
N
Y
N
Y 
Y
Y
8 (40%
) 
Breathing support
N
N
N
N
N
N
N
N
Y
N
3 (15%
) 
Neuro
M
RI
abnorm
al
norm
al
norm
al
norm
al
norm
al
norm
al
abnorm
al
abnorm
al
abnorm
al
abnorm
al
12 (60%
) 
EEG
norm
al
norm
al
norm
al
NA
norm
al
abnorm
al
NA
abnorm
al
abnorm
al
norm
al
4 (20%
) 
Seizure 
N
N
N
N
Y
N
N
Y 
Y
N
6 (30%
) 
Age at first seizure 
2 yo
5 yo
12yo
4 yo (9m
o ~ 12yo) 
Ataxia
Y
Y
N
N
Y
N
Y
Y
Y
N
13(65%
)
Vision
Glasses/contacts
N
N
Y
N
N
N
Y
N
N
N
6 (30%
) 
Vision acuity
NA
sunglasses
40/70
20/20
100%
NA
6/9.5
NA
NA
Strabism
us
Y
N
Y
N
N
N
Y
N
Y
N
8 (40%
) 
Dysm
orphic features
Sm
all ear lobes
NA
NA
N
NA
Y
N
N
N
N
NA
Upturned earlobes
NA
NA
Y
NA
N
Y
N
N
N
NA
Low
-set ears
NA
NA
Y
NA
N
N
N
N
N
NA
Protuberant ears
NA
NA
N
NA
N
Y
N
N
N
NA
Deep-set eyes
NA
NA
N
NA
N
N
N
N
N
NA
Upslanting palpebral fissures
NA
NA
Y
NA
N
N
N
N
N
NA
Dow
nslanting palpebral fissures
NA
NA
N
NA
N
N
N
N
N
NA
M
ild ptosis
NA
NA
Y
NA
N
Y
N
N
Y
NA
Esotropia
NA
NA
Y
NA
N
N
N
N
N
NA
Hypertelorism
NA
NA
Y
NA
N
N
Y
N
Y
NA
Flat nasal bridge
NA
NA
N
NA
N
N
N
N
Y
NA
M
icrognathia
NA
NA
N
NA
N
N
N
N
Y
NA
Thin upper lip
NA
NA
Y
NA
Y
Y
Y
N
Y
NA
Broad forehead
NA
NA
Y
NA
Y
N
Y
N
Y
NA
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TABLE S1: Additional candidate variants in considered in 5 patients. ‘GNOMAD’ indicates number of 
alleles reported in the gnomAD (Genome Aggregation Database: http://gnomad.broadinstitute.org); 
LOCAL indicates allele counts within internal Human Genome Sequencing Center databases.  
 
TABLE S2: Sources of data for clinical ascertainment 
 
Patient Assessment 
in Clinic 
Face to 
face 
meeting 
Medical 
Record 
Review 
Clinical 
Survey 
1 
 
X X X 
2 
 
X X X 
3 X X X X 
4 
  
X X 
5 
 
X X X 
6 
  
X X 
7 
 
X X X 
8 
  
X X 
9 
 
X 
 
X 
10 
 
X X X 
11 
  
X X 
12 
 
X 
 
X 
13 
  
X X 
14 
  
X X 
15 
  
X X 
16 X X X X 
17 
  
X X 
18 
 
X X X 
19 
 
X X X 
20 
  
X X 
PATIENT GENE MUTATION cDNA PROTEIN gnomAD LOCAL PHENOTYPE INHERITANCE FAMILY COMMENTS
Patient 3 KAT6B 10:76602922C>T c.307C>T p.Arg103Cys 45/277194 5/29642 Genitopatellar syndrome AD NA - no trio
Patient 3 SERPING1 11:57379324G>A c.1164G>A p.Met388Ile 31/277218 7/29642 Hereditary angioedema AD, AR NA - no trio
Patient 3 PKP2 12:32949166A>G c.2366T>C p.Ile789Thr 10/277068 0/29642
Arrhythmogenic right 
ventricular dysplasia AD NA - no trio
patient 6 NF1 c.3457_3460delCTCA p.Leu1153Metfs*4 de Novo
From supplied 
genetic report
Patient 10 GGN 19:38876427T>G c.1475A>C p.Gln492Pro  213/134120  278/29642 None known NA de Novo
Patient 10 LAMB3 1:209823322G>A c.170C>T p.Thr57Ile  30/277180 9/29642 Epidermolysis bullosa AR Father
Patient 10 LAMB3 1:209803163C>T c.1051G>A p.Glu351Lys  262/277236  33/29642 Epidermolysis bullosa AR Mother
Patient 14 ARID1A 1:27106208C>T c.5168C>T p.Pro1723Leu 2/246262 1/29642 Coffin-Siris syndrome AD NA - no trio
Patient 14 OPHN1 X:67283825G>T c.2029C>A p.Leu677Met 248/198097  24/29642
Mental retardation, X-
linked, with cerebellar 
hypoplasia and distinctive 
facial appearance XLR NA - no trio
Patient 14 AIPL1 17:6329101C>T c.834G>A p.Trp278Ter 91/269044 9/29642 Cone-rod dystrophy AR NA - no trio
Patient 14 ELN 7:73482987G>A c.2075G>A p.Gly692Asp 818/276770 134/29642 Cutis laxa AD NA - no trio
Patient 16 CD96 3:111319710C>T c.1036C>T p.Pro346Ser 55/276876 9/29642 Opitz trigonocephaly AD NA - no trio
Patient 16 FKRP 19:47259227A>T c.520A>T p.Ser174Cys 503/161236 42/29642
Congenital Muscular 
Dystrophy AR NA - no trio
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FIGURE S1: Conserved regions of AHDC1: Protein alignments illustrating conservation domains between 
human AHDC1 and its orthologs and homologs 
 
 
